MedTrace Logo

Assessment of Urinary Uromodulin and the Corresponding Gene Expression as a Biomarker of Diabetic Nephropathy

NCT05695573 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-12-22

No results posted yet for this study

Summary

Detecting diabetes-related kidney diseases early is crucial to prevent end-stage renal disease (ESRD). Existing biomarkers' specificity and sensitivity vary, emphasizing the need for novel markers. This research assesses urinary uromodulin levels and its gene expression, aiming to identify a potential marker for early diabetic nephropathy (DN) detection in type 2 diabetes patients. Uromodulin, encoded by the UMOD gene, is expressed mainly in the thick ascending limb of Henle's loop epithelial cells, making it a promising candidate for early DN detection and progression towards ESRD, potentially reducing chronic kidney disease prevalence.

Conditions

  • Diabetic Nephropathy

Interventions

DIAGNOSTIC_TEST

ACR, fasting, postprandial blood glucose ,HbA1c, creatinine, cystatin-C, BUN, Na, K , lipid profile

Use the ACR to divide diabetic patients to 3groups not normoalbuminuria, microalbuminuria, macroalbuminuria to evaluate the urinary uromodulin level and its exosomal umod mRNA as a potential biomarker of Diabetic nephropathy diagnosis

Sponsors & Collaborators

  • Ain Shams University

    collaborator OTHER

  • Tanta University

    lead OTHER

Principal Investigators

  • Tarek M mohamed, prof · Faculty of science, tanta university

  • Eman M Abd elAzeem, prof · faculty of science, Ain shams University

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-05
Primary Completion
2022-04-28
Completion
2022-06-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05695573 on ClinicalTrials.gov